Maintenance of Response With Icotrokinra, a Targeted Oral Peptide, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Randomized Treatment Withdrawal in …
1. 请及时下载文件确认是否正确, 系统将在 2026-08-30 22:40:42 删除文件
2. 如若文件有误请驳回应助文件, 求助状态即回到求助中
3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
J Soung, Y Cui, R Bissonnette, MG Lebwohl…
Journal of the American …, 2026
Elsevier
Continuous icotrokinra demonstrated superior maintenance of skin responses versus placebo through week 52 in adults with moderate-to-severe plaque psoriasis, indicating that once-daily icotrokinra can achieve and maintain skin clearance with a favorable safety profile.Data sharing statement The data sharing policy of Johnson

